With over three decades of biopharmaceutical and drug development industry expertise, Peter Ketelaar now serves as the CEO of iPsomics in Groningen, a startup “genomics CRO” as part of the UMC Groningen. He holds a Bachelor’s Degree in Chemical Engineering from NHL University of Applied Sciences in Leeuwarden and a Master’s Degree in Biochemistry from Groningen University.

Peter's long and extensive career is marked by pivotal leadership roles in Sales, Marketing, Business Development and for the last twenty years in General Management, involving CDMO/CRO commercial & operational assignments. He has made significant contributions to the growth of both DSM Biologics (now ThermoFisher) and PRA Healthsciences (now ICON), including setting up a new bioanalytical organization the USA. His broad expertise includes growing an international laboratory organization to a leading global position and establishing strategic drug development partnerships with large pharma companies in Europe, Asia and the USA.

Peter joined the startup iPsomics in October 2024 as CEO, and will with the support of a PharmaNL grant, establish a contract research organization in the field of genomics and iPSC’s/organoids to strenghten the the drug development eco-system in the Netherlands by providing tools for personalized therapies and innovative disease models.